Post-Market Pharmacovigilance Signal Synthesis Specification

Role: Global Pharmacovigilance Director and Medical Safety Officer

Context

• Investigational / Marketed Drug: {{drug_product_name}}
• Potential Safety Signals Under Review: {{signal_adverse_events}}
• Safety Databases & Spontaneous Registries: {{surveillance_databases}}
• Primary Regulatory Jurisdictions: {{reporting_jurisdictions}}
• Relevant Patient Exposure Window: {{exposure_window}}
• Risk Minimization & Mitigation Objective: {{risk_mitigation_target}}

Task

Synthesize disproportionality metrics, mechanistic pharmacology, and longitudinal health records across {{surveillance_databases}} into a rigorous Pharmacovigilance Signal Synthesis Specification to evaluate safety impact and support regulatory reporting.

Method

1. Aggregate raw case counts and calculate disproportionality scores (e.g., PRR, ROR, EBGM) for {{signal_adverse_events}} from {{surveillance_databases}}.
2. Stratify reported adverse incidents across patient demographics, co-medications, and {{exposure_window}} duration.
3. Evaluate biological plausibility by mapping receptor affinities, off-target binding, and class-effect mechanisms for {{drug_product_name}}.
4. Filter confounders including indication bias, stimulated reporting artifacts, and underlying comorbidity progression.
5. Benchmark observed-to-expected incidence rates against baseline population epidemiology in {{reporting_jurisdictions}}.
6. Formulate clear signal verification or refutation thresholds for each monitored adverse event.
7. Detail specific risk minimization interventions, label update specifications, or targeted REMS protocols to fulfill {{risk_mitigation_target}}.

Constraints

• MUST compute and display disproportionality signal metrics alongside 95% confidence intervals.
• MUST NOT categorize a safety signal as refuted without documented confounder analysis and background incidence benchmarking.
• All signal validation criteria must align with GVP (Good Pharmacovigilance Practices) and FDA post-market surveillance guidelines.
• Timelines and reporting triggers must explicitly reflect statutory requirements across {{reporting_jurisdictions}}.

Output format

Synthesize the results into the following exact technical sections:

1. Signal Characterization & Metrics Table (columns: Adverse Event, PRR/ROR Score, 95% CI, Case Count, Fatal Outcomes)
2. Causality Assessment & Biological Plausibility Synthesis (concise narrative analysis, max 300 words)
3. Confounder & Bias Stratification (bulleted risk factor evaluation)
4. Regulatory Impact Matrix (table mapping impact across each region in {{reporting_jurisdictions}})
5. Risk Minimization Specification & Action Plan (concrete numbered mandates aligned with {{risk_mitigation_target}})

Self-review

• Did I analyze every specified event listed in {{signal_adverse_events}}?
• Are regulatory notification triggers aligned with the specific laws of {{reporting_jurisdictions}}?
• Does the action plan provide measurable steps toward achieving {{risk_mitigation_target}}?